Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

The following is a summary of “Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer,” published ...

Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a ...

BOSTON - Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biotech company with a market capitalization of $631 ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU has been approved in the US for the treatment of adult patients with unresectable or metastatic ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo improved response rates and duration in BRAF V600E-mutant metastatic ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...